Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.805
+0.1051.21%
Volume:55.66M
Turnover:489.54M
Market Cap:101.45B
PE:22.16
High:8.850
Open:8.820
Low:8.685
Close:8.700
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.45
T/O Rate:0.48%
Dividend:0.34
Dividend Rate:3.83%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.31
PE(LYR):22.16
PS:2.77

Loading ...

CSPC Pharma Begins Phase I Trial of SYH2092, a Novel Amylin Receptor Agonist for Obesity Management

Bulletin Express
·
Aug 31

CSPC Pharma Advances Weight Management Pipeline With Phase 1 Trial Kickoff

Stock News
·
Aug 31

CSPC Pharma Wins China NMPA Clearance to Start Phase 1 Trial of Syh2092 Obesity Drug

Reuters
·
Aug 31

CSPC Pharmaceutical - Initiates Phase I Clinical Trial of Syh2092 Injection for Weight Management in China

THOMSON REUTERS
·
Aug 31

CSPC Pharmaceutical Group Stock Sheds 3.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 31

Movement Alert|CSPC PHARMA Declines 3.04% in Regular Trading, Trading at HK$9.215

Market Focus
·
Aug 31

CSPC Pharma Initiates Phase II Trial of SYH2069 Dual GLP-1/GIP Agonist for Obesity Management in China

Bulletin Express
·
Aug 28

CSPC Pharmaceutical Group Stock Sheds 1.5% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 28

CSPC Pharma Gets Trial Nod for Weight Management Drug in China

MT Newswires Live
·
Aug 27

CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China

Stock News
·
Aug 27

CSPC Pharma Secures NMPA Green Light for SYH2092, a Long-Acting Amylin Receptor Agonist Targeting Obesity and Type 2 Diabetes

Bulletin Express
·
Aug 27

CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection

Reuters
·
Aug 27

CSPC Pharmaceutical - Pharma Obtains China Clinical Trial Approval for Syh2092 Injection

THOMSON REUTERS
·
Aug 27

CSPC Pharmaceutical - Highly Potent Amylin Receptor Agonist (Syh2092 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Aug 27

CSPC PHARMA: DFZQ Disposes of Shares, Long Position Falls to 4.93%

HK Disclosure
·
Aug 27

CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus

Simply Wall St.
·
Aug 27

CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint

MT Newswires Live
·
Aug 26

CSPC Pharma’s EGFR-Targeted ADC SYS6010 Achieves Primary PFS Endpoint in Phase III NSCLC Trial

Bulletin Express
·
Aug 26

CSPC Pharmaceutical Gains U.S. FDA Fast Track Status for Novel PD-1/IL-15 Fusion Protein in Hard-to-Treat Metastatic Colorectal Cancer

Bulletin Express
·
Aug 26

CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment

Stock News
·
Aug 26